<SEC-DOCUMENT>0001445866-20-001623.txt : 20201027
<SEC-HEADER>0001445866-20-001623.hdr.sgml : 20201027
<ACCEPTANCE-DATETIME>20201027161720
ACCESSION NUMBER:		0001445866-20-001623
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20201027
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201027
DATE AS OF CHANGE:		20201027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		201264324

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utahmedcom-20201027.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2020-01-31' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK611ND10HVJLCM79P]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D201027' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D201027' id='fact2'>false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utahmedcom-20201027.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D201027'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2020-10-27</i:startDate>
<i:endDate>2020-10-27</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:14pt Times New Roman;margin:0;text-align:center'><b>UNITED STATES </b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'><b>Washington, D.C. &#160;20549</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><span style='font-size:14pt'><b>FORM </b><b><ix:nonNumeric name='dei:DocumentType' contextRef='D201027' escape='true'>8-K</ix:nonNumeric></b></span></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>CURRENT REPORT</b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;text-align:center'><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>Date of Report (date of earliest event reported): &#160;<ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D201027' format='ixt:datemonthdayyearen'>October 27, 2020</ix:nonNumeric></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:468pt'><tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:14pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D201027' escape='true'>UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D201027' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D201027' escape='true'>000-12575</ix:nonNumeric></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D201027' escape='true'>87-0342734</ix:nonNumeric></b></p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Commission File Number)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(IRS Employer</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>incorporation or organization)</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>Identification No.)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D201027' escape='true'>7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'> <span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D201027' escape='true'>Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D201027' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b><b> </b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D201027' escape='true'>84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Zip code)</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0'>Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b>Phone: </b><b>(</b><b><ix:nonNumeric name='dei:CityAreaCode' contextRef='D201027' escape='true'>801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D201027' escape='true'>566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:12pt Times New Roman;margin:0;text-align:center'><b>n/a</b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:WrittenCommunications' contextRef='D201027' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:SolicitingMaterial' contextRef='D201027' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementTenderOffer' contextRef='D201027' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementIssuerTenderOffer' contextRef='D201027' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Emerging growth company <ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D201027' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:11pt Times New Roman;margin:0;text-align:center'><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2020 and forward-looking statements relating to 2020 and beyond as presented in a press release dated October 27, 2020. &#160;The information in this report shall be deemed incorporated by reference into any registration statement heretofore or hereafter filed under the Securities Act of 1933, as amended, except to the extent that such information is superseded by information as of a subsequent date that is included in or incorporated by reference into such registration statement. The information in this report shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>The following is filed as an exhibit to this report: &#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse;width:476pt'><tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Exhibit</b></p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Number*</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Title of Document</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Location</b></p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b>Item 99.1</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><a href='utmd_ex99.1.htm' style='text-decoration:none'><span style='font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF'>Financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2020 and forward-looking statements relating to 2020 and beyond as presented in a press release dated October 27, 2020</span></a><span style='font-size:12pt'>.</span></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>This filing</p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>_______________________________________</p>
<p style='font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify'><kbd style='position:absolute;font:9pt Times New Roman;margin-left:-18pt'>*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><b>SIGNATURES</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Dated: October 27, 2020</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>By:</p>
</td><td valign='top' style='width:218.05pt;border-bottom:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:218.05pt;border-top:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99.1.htm
<DESCRIPTION>FINANCIAL INFORMATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK611ND10HVJLCM79P]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:10pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><B>UTMD Reports Financial Performance for Third Quarter and Nine Months of Year 2020</B></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'>Contact: Crystal Rios (801) 566-1200</KBD><KBD style=margin-left:360pt></KBD>October 27, 2020&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;For the third calendar quarter (3Q) and first nine months (9M) of 2020, Utah Medical Products, Inc. (Nasdaq: UTMD) reports financial results described by CEO Kevin Cornwell as follows,</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'>&#8220;As stockholders know, the desire to preserve capacity for treating patients with COVID-19 led to suspending many hospital medical procedures. &nbsp;As a result, UTMD began to experience lower demand for its specialty medical devices in March during 1Q 2020. &nbsp;As the largest segment of UTMD&#8217;s revenues in recent years has been in gynecology procedures deemed &#8220;nonessential&#8221; such as tubal ligation and loop excision of the transformation zone, UTMD sales dropped precipitously in 2Q 2020. </P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'>My view is that comparisons of 3Q and 9M 2020 results with the same periods in the prior year represent the magnitude of a revenue hole that UTMD fell into caused by COVID-19 management policies, not a fundamental trend. The trend which may be of more interest and cause for optimism is a comparison of successive quarterly revenues during 2020. &nbsp;In this report, in addition to comparing with the prior year&#8217;s same time periods, which identify the &#8220;COVID-19 hole&#8221;, UTMD also presents 2020 successive quarterly sales by channel and product group. &nbsp;In summary, 3Q 2020 U.S. domestic sales substantially recovered from 2Q 2020. &nbsp;Although sales outside the U.S. (OUS) have been slower to recover, they nevertheless were significantly higher in 3Q 2020 than in the dismal 2Q 2020. Unless governments again restrict medical care, we see the recovery trend continuing to be positive, so that 4Q 2020 is likely to be UTMD&#8217;s best revenue quarter of the year.&#8221; &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>Summary of Financial Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>UTMD management believes that the presentation of sequential 2020 quarterly results provides meaningful supplemental information to both management and investors. &nbsp;Keeping in mind that results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole, the following table shows the percent changes in 2020 quarterly results compared to the same periods of time in 2019:</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:203.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>Revenues [USD denominated]</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>1Q</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>2Q</FONT></P>
</TD><TD valign=top style='width:63pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>3Q</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>9M</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>U.S. domestic &nbsp;(excluding OEM)</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>+ 14.5%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(29.1%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(8.0%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>( &nbsp;9.2%)</P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Canada domestic</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(21.7%)</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(62.9%)</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>( 5.6%)</P>
</TD><TD valign=top style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(32.0%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Ireland domestic</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(26.2%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(48.6%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(18.1%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(30.9%)</P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>UK domestic</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(11.2%)</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(72.8%)</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(34.4%)</P>
</TD><TD valign=top style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(38.7%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>France domestic</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(11.8%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(72.1%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(12.3%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(32.6%)</P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Australia domestic</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>( &nbsp;8.6%)</FONT></P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(43.0%)</FONT></P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(13.6%)</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(22.0%)</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Subtotal, Direct to End User:</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>+ 4.2%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(39.1%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(11.1%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(16.3%)</P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>All Other OUS (Sales to Int&#8217;l Distributors)</P>
</TD><TD valign=top style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'> ( &nbsp;5.2%)</P>
</TD><TD valign=top style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>( &nbsp;4.5%)</P>
</TD><TD valign=top style='width:63pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(34.7%)</P>
</TD><TD valign=top style='width:67.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(15.6%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>U.S. OEM Sales</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>+ 0.7%</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>+ 9.5%</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>( 8.9%)</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>( &nbsp;0.6%)</FONT></P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Worldwide Revenues</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>+ 1.6%</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(25.8%)</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(16.1%)</P>
</TD><TD valign=top style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(14.0%)</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>1</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>UTMD subsidiary direct domestic sales in Canada, Ireland, the United Kingdom, France and Australia are invoiced in foreign currencies. Foreign currency exchange (FX) rates for income statement purposes are transaction-weighted averages. The average rates from the applicable foreign currency to USD during 3Q 2020 and 9M 2020 compared to the same periods in 2019 follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:66.9pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 20</FONT></P>
</TD><TD valign=top style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 19</FONT></P>
</TD><TD valign=top style='width:68.3pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:67pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 20</FONT></P>
</TD><TD valign=top style=width:67.05pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 19</FONT></P>
</TD><TD valign=top style=width:68.35pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:66.9pt><P align=right style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>1.295</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>1.233</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:68.3pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>+ 5.0%</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:67pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1.279</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:67.05pt><P align=center style='font:11pt Times New Roman;margin:0'>1.273</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:68.35pt><P align=center style='font:11pt Times New Roman;margin:0'>+ 0.5%</P>
</TD></TR>
<TR><TD valign=bottom style=width:66.9pt><P align=right style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=bottom style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>1.173</P>
</TD><TD valign=bottom style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>1.108</P>
</TD><TD valign=bottom style='width:68.3pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>+ 5.8%</P>
</TD><TD valign=bottom style='width:67pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1.128</P>
</TD><TD valign=bottom style=width:67.05pt><P align=center style='font:11pt Times New Roman;margin:0'>1.123</P>
</TD><TD valign=bottom style=width:68.35pt><P align=center style='font:11pt Times New Roman;margin:0'>+ 0.4%</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:66.9pt><P align=right style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>0.714</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>0.687</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:68.3pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>+ 4.0%</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:67pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>0.677</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:67.05pt><P align=center style='font:11pt Times New Roman;margin:0'>0.700</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:68.35pt><P align=center style='font:11pt Times New Roman;margin:0'>( 3.3%)</P>
</TD></TR>
<TR><TD valign=bottom style=width:66.9pt><P align=right style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=bottom style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>0.751</P>
</TD><TD valign=bottom style=width:67pt><P align=center style='font:11pt Times New Roman;margin:0'>0.758</P>
</TD><TD valign=bottom style='width:68.3pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>( 0.8%)</P>
</TD><TD valign=bottom style='width:67pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>0.745</P>
</TD><TD valign=bottom style=width:67.05pt><P align=center style='font:11pt Times New Roman;margin:0'>0.752</P>
</TD><TD valign=bottom style=width:68.35pt><P align=center style='font:11pt Times New Roman;margin:0'>( 1.0%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Although the volatility of &nbsp;FX rates for OUS sales when consolidated in USD terms continues to impact period-to-period relative financial results because of UTMD&#8217;s significant percentage of foreign currency sales, the FX rate impact in 9M 2020 was less significant than in the recent past. Except for the CAD FX rate which had not changed as significantly as other currencies, a healthy 3Q 2020 decline in the USD offset its strengthening during the first half of the year. Foreign currency revenues in 3Q 2020 were increased by $85 as a result of a weaker USD compared to 3Q 2019. &nbsp;In contrast, the difference in period-to-period FX rates reduced revenues by $36 in 9M 2020. &nbsp;Foreign currency sales as a percentage of total sales were 21.0% of total sales in 3Q 2020 and 22.0% of total sales in 9M 2020. &nbsp;UTMD&#8217;s 3Q 2019 and 9M 2019 revenues invoiced in foreign currencies represented 23.6% and 27.2% of total consolidated USD sales respectively.</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Other factors that affected period-to-period revenue comparisons included </P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>International distributors&#8217; quarter-to-quarter orders fluctuate more than domestic end user orders.&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>1Q 2019 was a partial quarter of U.S. domestic Filshie Clip System (Filshie device) sales, as the UTMD acquisition of the Cooper Surgical Inc (CSI) exclusive Filshie device distribution rights took effect February 1, 2019.&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD profit margins in 3Q 2020 and 9M 2020 compared to 3Q 2019 and 9M 2019 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:493.1pt;margin-left:-1.7pt><TR><TD valign=top style=width:236.6pt><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>3Q 2020 </P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(Jul &#8211;&nbsp;Sep)</FONT></P>
</TD><TD valign=top style='width:63.8pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>3Q &nbsp;2019</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jul &#8211;&nbsp;Sep)</FONT></P>
</TD><TD valign=top style='width:63.75pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>9M &nbsp;2020</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Sep)</FONT></P>
</TD><TD valign=top style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>9M &nbsp;2019</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Sep)</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:236.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (gross profits/ sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>62.0%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63.8pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>59.1% </P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63.75pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>60.6%</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>61.7%</P>
</TD></TR>
<TR><TD valign=top style=width:236.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (operating profits/ sales):</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>34.2%</P>
</TD><TD valign=top style='width:63.8pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>35.0%</P>
</TD><TD valign=top style='width:63.75pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>31.3%</P>
</TD><TD valign=top style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>36.9%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:236.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin (profit after taxes/ sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>28.0% </P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63.8pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>29.7%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63.75pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>25.2%</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>29.6%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>For the following income statement categories, the above profit margins together with changes in revenues translated into sequential 2020 quarterly percentage changes compared to the same periods in 2019:</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style='width:203.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>Consolidated Income Statement</FONT></P>
</TD><TD valign=top style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>1Q</FONT></P>
</TD><TD valign=top style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>2Q</FONT></P>
</TD><TD valign=top style='width:63pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>3Q</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>9M</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Worldwide Revenues</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>+ 1.6%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(25.8%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(16.1%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(14.0%)</P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Gross Profit</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>+ 0.9%</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(34.0%)</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(12.0%)</P>
</TD><TD valign=top style='width:67.5pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(15.6%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Operating Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'> &nbsp;( 5.8%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(55.9%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(17.9%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(27.2%)</P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Earnings Before Income Tax</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'> &nbsp;( 3.6%)</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(56.7%)</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(19.3%)</P>
</TD><TD valign=top style='width:67.5pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(27.4%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:203.4pt;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Net Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>-</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(62.8%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(20.8%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(28.8%)</P>
</TD></TR>
<TR><TD valign=top style='width:203.4pt;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Earnings Per Share</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>-</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(62.0%)</P>
</TD><TD valign=top style='width:63pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(19.0%)</P>
</TD><TD valign=top style='width:67.5pt;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>(27.6%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In the following income statement summary, please refer to the right two columns in the table just above for a comparison of 3Q 2020 and 9M 2020 income statement results with the same periods in 2019. &nbsp;More detail is provided later in this report.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>2</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Gross Profit in 3Q 2020 declined less than the sales decline primarily as a result of sales mix. The 9M 2020 gross profit margin (GPM), gross profit divided by sales, was lower than in 9M 2019 despite the better 3Q GPM because 14% lower sales during 9M 2020 absorbed marginally less of UTMD&#8217;s fixed critical mass of manufacturing overhead. Because UTMD believes that the lower sales are transitory, knows it can remain very profitable even at the lower sales levels experienced during the pandemic and has a significant cash reserve relative to operational needs, management will not cut important resources and sacrifice future capabilities just to maintain short term profit margins. </P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Operating Income declined more than gross profit in both 3Q 2020 and 9M 2020 because UTMD&#8217;s non-cash identifiable intangible asset (IIA) amortization expense included in operating expenses was 15.5% of sales in 3Q 2020 compared to 12.8% of sales in 3Q 2019, and 16.0% in 9M 2020 compared to 12.7% in 9M 2019. &nbsp;This was due not only to the lower sales in 2020 (less absorption of a fixed expense) but also the GBP FX rate difference in the 3Q and the timing of beginning the CSI IIA amortization in 2019.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Earnings before tax (EBT) declined more than operating income simply because UTMD did not receive interest on its cash balances in 2020 like it did in 2019, although average cash balances were about 20% higher during 9M 2020. &nbsp;Net Income declined slightly more than EBT as a result of the sovereignty mix of taxable profits in 2020 compared to 2019. &nbsp;The lowest tax regimes of Ireland and the UK had the greatest declines in EBT. Finally, Earnings Per Share (EPS) declined less than net income as a result of the benefit of share repurchases in 2020.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s FX rates for balance sheet purposes are the applicable rates at the <FONT style='border-bottom:1px solid #000000'>end</FONT> of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of September 2020 and the end of September 2019 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:319.05pt;margin-left:91.5pt><TR style=height:15.65pt><TD valign=bottom style=width:53.55pt><P style='font:12pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:53.55pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style=width:82.55pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'><FONT style='border-bottom:1px solid #000000'>Sep 30, 2020</FONT></P>
</TD><TD valign=middle style=width:75.85pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'><FONT style='border-bottom:1px solid #000000'>Sep 30, 2019</FONT></P>
</TD><TD valign=bottom style=width:53.55pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR style=height:15.65pt><TD valign=middle bgcolor=#CCEEFF style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>GBP</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#CCEEFF style=width:82.55pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>1.292</P>
</TD><TD valign=middle bgcolor=#CCEEFF style=width:75.85pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>1.230</P>
</TD><TD valign=middle bgcolor=#CCEEFF style=width:53.55pt><P align=right style='font:11pt Times New Roman;margin:0;color:#000000'>+ 5.0%</P>
</TD></TR>
<TR style=height:15.65pt><TD valign=middle style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>EUR</P>
</TD><TD valign=bottom style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:82.55pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>1.172</P>
</TD><TD valign=middle style=width:75.85pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>1.091</P>
</TD><TD valign=middle style=width:53.55pt><P align=right style='font:11pt Times New Roman;margin:0;color:#000000'>+ 7.5%</P>
</TD></TR>
<TR style=height:15.65pt><TD valign=middle bgcolor=#CCEEFF style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>AUD</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#CCEEFF style=width:82.55pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>0.716</P>
</TD><TD valign=middle bgcolor=#CCEEFF style=width:75.85pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>0.675</P>
</TD><TD valign=middle bgcolor=#CCEEFF style=width:53.55pt><P align=right style='font:11pt Times New Roman;margin:0;color:#000000'>+ 6.1%</P>
</TD></TR>
<TR style=height:15.65pt><TD valign=middle style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>CAD</P>
</TD><TD valign=bottom style=width:53.55pt><P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:82.55pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>0.751</P>
</TD><TD valign=middle style=width:75.85pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>0.755</P>
</TD><TD valign=middle style=width:53.55pt><P align=right style='font:11pt Times New Roman;margin:0;color:#000000'>( 0.6%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s September 30, 2020 Balance Sheet remained strong with an absence of debt. During 2020, inventories declined $0.6 million despite much lower sales, which is an indication of good manufacturing planning and control. Due to the increase in value of the GBP, EUR and AUD noted above, despite depreciation of fixed assets, the USD net book value of fixed assets in the UK, Ireland and Australia increased $0.6 million as of September 30, 2020 from September 30, 2019. Over the one year period of time, the intangible asset balance declined $5.5 million, about 12%. &nbsp;Ending cash and investments were $46.3 million on September 30, 2020 compared to $42.8 million on December 31, 2019, after paying $3.1 million in cash dividends to stockholders and repurchasing $7.0 million in UTMD stock during 9M 2020. After reducing stockholders&#8217; equity a combined $10.1 million in 9M 2020 stockholder dividends and share repurchases, September 30, 2020 stockholders&#8217; equity was down only $2.7 million from December 31, 2019. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 3Q 2020 UTMD sales were $2,016 (16.1%) lower than in 3Q 2019. Constant currency sales were $2,101 (16.8%) lower. Total consolidated 9M 2020 UTMD sales were $4,905 (14.0%) lower than in 9M 2019.  Constant currency sales in 9M 2020 were $4,869 (13.9%) lower than in 9M 2019. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In 3Q 2020 compared to 3Q 2019, U.S. domestic sales were 8% lower and OUS sales were 28% lower.   In 9M 2020 compared to 9M 2019, U.S. domestic sales were 7% lower and OUS sales were 23% lower.  </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>3</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Domestic sales in 3Q 2020 were $6,950 compared to $7,575 in 3Q 2019. &nbsp;Domestic sales in 9M 2020 were $18,906 compared to $20,366 in 9M 2019. &nbsp;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie Clip System (&#8220;Filshie device&#8221;) sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) Filshie device sales direct to U.S. medical facilities starting in February 2019. &nbsp;Domestic direct sales in 3Q 2020 excluding Filshie devices, representing 50% of total domestic sales, were $178 (5%) lower than in 3Q 2019. &nbsp;Domestic direct sales in 9M 2020 excluding Filshie devices, representing 51% of total domestic sales, were $1,078 (10%) lower than in 9M 2019. OEM sales in 3Q 2020, representing 25% of total domestic sales, were $172 (9%) lower than in 3Q 2019. OEM sales in 9M 2020, also representing 25% of total domestic sales, were $27 (1%) lower than in 9M 2019. Filshie device sales direct to U.S. domestic end-user facilities were $275 (14%) lower in 3Q 2020 compared to sales in 3Q 2019. &nbsp;Filshie device sales direct to U.S. domestic end-user facilities were $355 (7%) lower in 9M 2020 compared to Filshie device sales in 9M 2019. &nbsp;Because Filshie device sales are a significant portion of UTMD&#8217;s domestic business and a UTMD device most affected by the COVID-19 pandemic, management believes the following table might help to see the overall 2020 pandemic impact and recovery trend:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Filshie device sequential quarterly USD direct sales in the U.S. </P>
<TABLE style=border-collapse:collapse><TR><TD valign=bottom style=width:203.4pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Year</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>1Q</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>2Q</FONT></P>
</TD><TD valign=top style='width:63pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>3Q</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>9M</FONT></P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:203.4pt><P align=right style='font:11pt Times New Roman;margin:0'>2020</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,689</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,135</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:63pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,733</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>4,557</P>
</TD></TR>
<TR><TD valign=bottom style=width:203.4pt><P align=right style='font:11pt Times New Roman;margin:0'>2019</P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>925</P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,979</P>
</TD><TD valign=top style='width:63pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>2,008</P>
</TD><TD valign=top style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>4,912</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS sales in 3Q 2020 were $3,528 compared to $4,919 in 3Q 2019. &nbsp;OUS sales in 9M 2020 were $11,262 compared to $14,707 in 9M 2019. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS sales invoiced in GBP, EUR, AUD and CAD currencies were $85 higher in 3Q 2020 and $36 lower in 9M 2020 as a result of changes in FX rates. Foreign currency OUS sales in 3Q 2020 were $2,205, which was 62% of all OUS sales and 21% of total consolidated sales. &nbsp;In comparison, foreign currency OUS sales in 3Q 2019 were $2,944, which was 60% of all OUS sales and 24% of total consolidated sales. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The foreign currency OUS sales in 9M 2020 were $6,653, which was 59% of all OUS sales and 22% of total consolidated sales. &nbsp;In comparison, foreign currency OUS sales in 9M 2019 were $9,534, which was 65% of all OUS sales and 27% of total consolidated sales.  Because Filshie device sales are also a significant portion of UTMD&#8217;s OUS business and an implanted device most affected by the COVID-19 pandemic, management believes the following table might help to see the overall 2020 pandemic impact and recovery trend:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Filshie device sequential quarterly USD-denominated sales OUS: </P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:203.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Year</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>1Q</FONT></P>
</TD><TD valign=top style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>2Q</FONT></P>
</TD><TD valign=top style='width:63pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>3Q</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>9M</FONT></P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:203.4pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Direct &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,798</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:63pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>681</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,426</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>3,905</P>
</TD></TR>
<TR><TD valign=bottom style='width:203.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2019</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>2,135</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>2,036</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,810</P>
</TD><TD valign=bottom style='width:67.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>5,981</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style='width:203.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distributor &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>318</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>323</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>133</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>774</P>
</TD></TR>
<TR><TD valign=bottom style='width:203.4pt;border-bottom:3px double #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2019</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:3px double #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>494</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:3px double #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>487</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:3px double #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>437</P>
</TD><TD valign=bottom style='width:67.5pt;border-left:0.5pt solid #000000;border-bottom:3px double #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>1,418</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style='width:203.4pt;border-top:3px double #000000'><P align=right style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total OUS &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-top:3px double #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>2,117</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-top:3px double #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>1,003</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:63pt;border-top:3px double #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>1,559</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:67.5pt;border-top:3px double #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>4,679</P>
</TD></TR>
<TR><TD valign=bottom style='width:203.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt'>2019</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>2,630</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>2,523</P>
</TD><TD valign=bottom style='width:63pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>2,246</P>
</TD><TD valign=bottom style='width:67.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:3pt;margin-bottom:0pt;margin-right:-6.5pt'>7,399</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>OUS Filshie sales obviously took a deeper hit from the pandemic than in the U.S. </P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>UTMD segments sales into the following general product categories: &nbsp;gynecology/ electrosurgery, labor &amp; delivery, neonatal, and miscellaneous including blood pressure monitoring kits and accessories as well as related OEM products. &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>4</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>In 3Q 2020 compared to 3Q 2019, worldwide gynecology/ electrosurgery device sales were down 21%, worldwide labor &amp; delivery device sales were essentially the same, worldwide neonatal device sales were down 6% and worldwide blood pressure monitoring and related OEM product sales were down 18%. Devices in the gynecology/ electrosurgery category were mostly classified as &#8220;nonessential&#8221; during the pandemic. &nbsp;In the blood pressure monitoring category, UTMD&#8217;s largest OUS distributor took a double quarterly shipment in 3Q 2019.</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>In 9M 2020 compared to 9M 2019, worldwide gynecology/ electrosurgery device sales were down 22%, worldwide labor &amp; delivery device sales were down 13%, worldwide neonatal device sales were down 2% and worldwide blood pressure monitoring and related OEM product sales were down 3%.</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>Gross Profit</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Gross Profit results from subtracting the costs of manufacturing and shipping products to customers from revenues. &nbsp;Gross Profit was $883 (12.0%) lower in 3Q 2020 than in 3Q 2019, and $3,369 (15.6%) lower in 9M 2020 than in 9M 2019. &nbsp;UTMD&#8217;s 3Q 2020 GPM improved to 62.0% compared to 59.1% in 3Q 2019 so that the decline in 3Q Gross Profit was not as significant as the 3Q decline in sales. Sales to international distributors are at lower prices for the same devices because the distributor incurs direct marketing expenses instead of UTMD. &nbsp;Sales to international distributors were only 18% of total sales in 3Q 2020 compared to 23% in 3Q 2019. The 3Q 2019 GPM was also exceptionally low because of a &#8220;double&#8221; shipment of blood pressure monitoring kits to UTMD&#8217;s China distributor. For 9M 2020 compared to 9M 2019, Gross Profit declined slightly more than the sales decline as a result of UTMD not cutting critical manufacturing overhead resources, and providing special incentives in 2Q 2020 for employees to come to work. Nevertheless, the 60.6% GPM for the 2020 year to date has met management&#8217;s long term objective. </P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>Operating Income</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Operating Income results from subtracting Operating Expenses from Gross Profit. Operating Expenses, comprised of general and administrative (G&amp;A) expenses, sales and marketing (S&amp;M) expenses and product development (R&amp;D) expenses, were 27.8% of sales in 3Q 2020 compared to 24.1% of sales in 3Q 2019. &nbsp;Operating Expenses were 29.4% of sales in 9M 2020 compared to 24.8% of sales in 9M 2019. Although the operating expense percentage of sales increased due to the 2020 short term pandemic reduction in sales, management continued to tightly manage operating expenses without sacrificing resources needed for longer term growth.</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Summary comparison of (USD) consolidated operating expenses:</P>
<TABLE style=border-collapse:collapse;margin-left:0.9pt><TR><TD valign=top style=width:130.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2020</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2019</FONT></P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2020</FONT></P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2019</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:130.5pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;&nbsp;352</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;&nbsp;421</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 1,195</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;1,304</P>
</TD></TR>
<TR><TD valign=top style=width:130.5pt><P style='font:11pt Times New Roman;margin:0'>R&amp;D Expense</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:11pt Times New Roman;margin:0'>125</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>130</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>375</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>357</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:130.5pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;2,432</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;2,457</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;7,285</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;7,037</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:130.5pt><P style='font:11pt Times New Roman;margin:0'>Total Operating Expenses:</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:11pt Times New Roman;margin:0'> $ 2,909</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 3,008</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 8,855</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 8,698</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Lower S&amp;M expenses were due primarily to the lack of trade show expenses during the pandemic. S&amp;M expenses were 3.4% of sales in both 3Q 2020 and 3Q 2019.  S&amp;M expenses were 4.0% of sales in 9M 2020 compared to 3.7% of sales in 9M 2019. &nbsp;&nbsp; &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>R&amp;D expenses were consistent with the prior year&#8217;s same periods of time, varying only by specific project expenses. R&amp;D expenses were 1.2% of sales in 3Q 2020 compared to 1.0% of sales in 3Q 2019. R&amp;D expenses in 9M 2019 were also 1.2% of sales compared to 1.0% of sales in 9M 2019.  &nbsp; </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The higher G&amp;A expense in 9M 2020 was due to amortization expense of the CSI IIA for a full quarter in 1Q 2020 compared to a partial quarter in 1Q 2019. &nbsp;Consolidated G&amp;A expenses were 23.2% of sales in 3Q 2020 compared to 19.7% of sales in 3Q 2019.  Consolidated G&amp;A expenses were 24.1% of sales in </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>5</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>9M 2020 compared to 20.1% of sales in 9M 2019. &nbsp;G&amp;A expenses included non-cash expense from the amortization of IIA resulting from the March 2011 Femcare Group Ltd (UK) acquisition and the amortization of IIA from the purchase of the CSI U.S. exclusive Filshie devices distribution rights effective in February 2019. &nbsp;</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The initial amount of IIA for the 2011 Femcare UK purchase was &#163;23,998. &nbsp;After 9.5 years of amortization, the IIA balance is &#163;8,686. &nbsp;For both years of 2020 and 2019, the amortization expense rate was a constant &#163;399 per calendar quarter. The USD amortization expense amount in each period, however, varied according to the USD/GBP FX rate. </P>
<P style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The initial amount of IIA for the 2019 acquisition of 4.75 years&#8217; remaining exclusive U.S. Filshie device distribution rights from CSI was $21,000. &nbsp;The straight-line amortization of this IIA is $1,105/ calendar quarter over the remaining 4.75 years of the prior distribution agreement. After 20 months of amortization, the CSI IIA balance as of September 30, 2020 is $13,632. &nbsp;The difference in 9M CSI IIA amortization expense is due to the start of the amortization in February 2019, i.e. 9 months of expense in 2020 through September versus 8 months in 2019. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Because the IIA amortization expenses represent a significant portion of UTMD&#8217;s G&amp;A expenses, UTMD provides the following table that separates the IIA amortization expenses from all other G&amp;A expenses:</P>
<TABLE style=border-collapse:collapse;margin-left:0.9pt><TR style=height:11.05pt><TD valign=top style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2020</FONT></P>
</TD><TD valign=top style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2019</FONT></P>
</TD><TD valign=top style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2020</FONT></P>
</TD><TD valign=top style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2019</FONT></P>
</TD></TR>
<TR style=height:11.05pt><TD valign=top bgcolor=#CCEEFF style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'>IIA amortization expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;1,621</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;1,597</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 4,839</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;&nbsp;4,471</P>
</TD></TR>
<TR style=height:11.05pt><TD valign=top style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'>All other G&amp;A expense</P>
</TD><TD valign=top style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;811</FONT></P>
</TD><TD valign=top style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;860</FONT></P>
</TD><TD valign=top style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;2,445</FONT></P>
</TD><TD valign=top style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;2,566</FONT></P>
</TD></TR>
<TR style=height:12.6pt><TD valign=top bgcolor=#CCEEFF style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total G&amp;A Expenses:</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'> $ 2,432</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 2,457</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 7,284</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 7,037</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;margin-left:0.9pt><TR style=height:11.05pt><TD valign=top bgcolor=#CCEEFF style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Sales:</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2020</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2019</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2020</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2019</FONT></P>
</TD></TR>
<TR style=height:11.05pt><TD valign=top style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'>IIA amortization expense</P>
</TD><TD valign=top style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;15.5%</P>
</TD><TD valign=top style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'>12.8%</P>
</TD><TD valign=top style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'>16.0%</P>
</TD><TD valign=top style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;12.8%</P>
</TD></TR>
<TR style=height:11.05pt><TD valign=top bgcolor=#CCEEFF style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'>All other G&amp;A expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;7.7%</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6.9% &nbsp;&nbsp;</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;8.1%</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;7.3%</FONT></P>
</TD></TR>
<TR style=height:12.6pt><TD valign=top style=width:152.8pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total G&amp;A Expenses:</P>
</TD><TD valign=top style=width:84.3pt><P align=right style='font:11pt Times New Roman;margin:0'> 23.2%</P>
</TD><TD valign=top style=width:68.45pt><P align=right style='font:11pt Times New Roman;margin:0'>19.7%</P>
</TD><TD valign=top style=width:79pt><P align=right style='font:11pt Times New Roman;margin:0'>24.1%</P>
</TD><TD valign=top style=width:63.2pt><P align=right style='font:11pt Times New Roman;margin:0'>20.1%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Eventually, when the two Filshie-related IIA balances are fully amortized, stockholders can look forward to a substantial increase in EBT. The Femcare acquisition IIA amortization expense has 5.5 more years to run at about $516 per quarter using the same 1.295 USD/GBP FX rate as in 3Q 2020. &nbsp;The CSI IIA amortization expense has 3.1 more years to run at $1,105 per quarter. &nbsp;Stockholders will appreciate that, although cash flow will not be affected, annualized reported EPS will increase $.90 after another 3.1 years, based on current shares outstanding and if current U.S. and Utah income tax rates remain the same. Similarly, after another 5.5 years annualized EPS would be $1.36 higher based on current shares outstanding and unchanged income tax rates. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Other G&amp;A expenses were lower in both periods primarily because UTMD&#8217;s CEO has taken 50% salary in 2020 compared to 2019, and 2020 management bonuses based on the projected 2020 annual EBT have been accrued at a lower rate than in 2019. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In summary, Operating Income in 3Q 2020 was $3,588 (34.2% of sales) compared to $4,371 (35.0% of sales) in 3Q 2019. &nbsp;Operating Income in 9M 2020 was $9,428 (31.3% of sales) compared to $12,954 (36.9% of sales) in 9M 2019. &nbsp;Lower gross profits in 2020 were leveraged down further by higher IIA amortization expense absorbed by fewer sales. In any event, the operating income margins achieved in 2020 were excellent compared to industry peers.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense or adding net non-operating income from or to, as applicable, Operating Income.  Consolidated 3Q 2020 EBT was $3,588 (34.2% of sales) compared to </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>6</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>$4,448 (35.6% of sales) in 3Q 2019.  Consolidated 9M 2020 EBT was $9,553 (31.7% of sales) compared to $13,150 (37.5% of sales) in 9M 2019.  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>For UTMD, non-operating expenses include bank fees, losses from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms, and losses from the disposition of fixed assets. &nbsp;Non-operating income includes income from rent of underutilized property; investment income; gains from remeasuring the value of EUR or GBP bank balances, as applicable; and gains from the disposition of fixed assets.  Net non-operating income results from subtracting non-operating expenses from gross non-operating income. &nbsp;UTMD&#8217;s net non-operating income in 3Q 2020 was less than $1 compared to $76 in 3Q 2019. &nbsp;Net non-operating income in 9M 2020 was $126 compared to $196 in 9M 2019. &nbsp;  &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The EBT of Utah Medical Products, Inc. in the U.S. was $6,469 in 9M 2020 compared to $8,674 in 9M 2019. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 2,393 in 9M 2020 compared to EUR 2,157 in 9M 2019. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (297) in 9M 2020 compared to GBP 1,449 in 9M 2019. The 9M 2020 EBT of Utah Medical Products Canada, Inc. (dba Femcare Canada) was CAD 565 in 9M 2019 compared to CAD 926 in 9M 2019. &nbsp;The EBT of UTMD&#8217;s manufacturing subsidiaries varies as a result of intercompany shipments which are eliminated in the consolidation of results. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that UTMD management believes is of interest to investors because it provides meaningful supplemental information to both management and investors that represents profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Although the U.S. Securities and Exchange Commission advises that EBITDA is a non-GAAP metric, UTMD&#8217;s non-US GAAP EBITDA is the sum of the following elements in the table below, each of which is a US GAAP number: &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:441pt;margin-left:5.4pt><TR><TD valign=top style=width:193.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>3Q 2020</FONT></P>
</TD><TD valign=top style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2019</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2020</FONT></P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2019</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:193.5pt><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>$ &nbsp;3,588</P>
</TD><TD valign=top style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 4,448</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 9,553</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>$13,150</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:193.5pt><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>160</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>171</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>495</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>526</P>
</TD></TR>
<TR><TD valign=top style=width:193.5pt><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>516</P>
</TD><TD valign=top style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>492</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,523</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>1,524</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:193.5pt><P style='font:11pt Times New Roman;margin:0'>CSI IIA Amortization Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>3,316</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>2,947</P>
</TD></TR>
<TR><TD valign=top style=width:193.5pt><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>13</P>
</TD><TD valign=top style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>13</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>37</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>41</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:193.5pt><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>49</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>29</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>121</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>85</P>
</TD></TR>
<TR><TD valign=top style='width:193.5pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:81pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2</P>
</TD><TD valign=top style='width:54pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(41)</P>
</TD><TD valign=top style='width:54pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>44</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:193.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:81pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 5,433</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:54pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 6,255</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$15,004</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:54pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$18,317</P>
</TD></TR>
<TR><TD valign=top style=width:193.5pt><P align=right style='font:11pt Times New Roman;margin:0'>Period to Period Change:</P>
</TD><TD valign=top style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>(13.2%)</P>
</TD><TD valign=top style='width:54pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(18.1%)</P>
</TD><TD valign=top style=width:54pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In summary, UTMD&#8217;s 3Q 2020 non-US GAAP EBITDA declined 13.2% compared to a 19.3% decline in EBT, and 9M 2020 non-US GAAP EBITDA declined 18.1% compared to a 27.4% decline in EBT. Management believes that the non-US GAAP EBITDA decline is more indicative of the COVID-19 negative impact on UTMD&#8217;s 2020 operating results than the change represented by EBT.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>Net Income in 3Q 2020 was $2,933 (28.0% of sales) compared to $3,705 (29.7% of sales) in 3Q 2019. The average consolidated income tax provision (as a % of EBT) in 3Q 2020 was 18.3% compared to 16.7% in 3Q 2019. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Net Income in 9M 2020 was $7,386 (24.5% of sales) compared to Net Income of $10,369 (29.6% of sales) in 9M 2019. &nbsp;Net Income in 9M 2020 included a 2Q 2020 unfavorable $225 tax provision increase for a future UK income tax increase on non-deductible IIA amortization expense over the next six years. &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>7</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>The average consolidated income tax provisions (as a % of EBT) in 9M 2020 and 9M 2019 were 22.7% and 21.1%, respectively. </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted EPS in 3Q 2020 were $.803 compared to $.991 in 3Q 2019. &nbsp;Diluted EPS in 9M 2020 were $2.008 compared to $2.774 in 9M 2019. &nbsp;According to U.S. GAAP, the UK tax law change in 2Q 2020 which increased UTMD&#8217;s deferred tax liability, to be amortized over the next six years, was recognized as an income tax provision increase in the 2Q 2020 income statement. Without the 2Q 2020 $225 tax provision adjustment, 9M 2020 EPS were $2.069. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted shares were 3,653,500 in 3Q 2020 compared to 3,737,335 in 3Q 2019, and 3,678,210 in 9M 2020 compared to 3,738,056 in 9M 2019. &nbsp;The lower diluted shares in 9M 2020 were the combined result of 80,000 shares repurchased in 1Q 2020, 7,000 shares repurchased in 3Q 2020, 5,614 employee option exercises in 9M 2020 and an employee option award of 26,300 shares in March 2020. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Outstanding shares at the end of 3Q 2020 were 3,640,371 compared to 3,721,757 at the end of calendar year 2019. The difference was due to employee option exercises of 5,614 during 9M 2020 offset by 87,000 shares repurchased in the open market. Outstanding shares were 3,720,344 one year ago at the end of 3Q 2019. The number of shares used for calculating diluted EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. &nbsp;The total number of outstanding unexercised employee and outside director options at September 30, 2020 was 71,700 at an average exercise price of $65.80, including shares awarded but not yet vested. &nbsp;This compares to 51,690 unexercised option shares at the end of 2019 at an average exercise price of $58.50/ share, including shares awarded but not yet vested.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The number of shares added as a dilution factor in 3Q 2020 was 11,130 compared to 17,588 in 3Q 2019. The number of shares added as a dilution factor in 9M 2020 was 14,514 compared to 16,435 in 9M 2019. In March 2020, 26,300 option shares were awarded to 48 employees at an exercise price of $77.05 per share. No options were awarded in 2019. &nbsp;UTMD paid $1,020 ($0.280/share) in dividends to stockholders in 3Q 2020 compared to $1,028 ($0.275/ share) paid in 3Q 2019. Dividends paid to stockholders during 3Q 2020 were 35% of 3Q 2020 Net Income. &nbsp;UTMD paid $3,097 ($0.280/share) in dividends to stockholders in 9M 2020 compared to $3,083 ($0.275/ share) paid in 9M 2019. Dividends paid to stockholders during 9M 2020 were 41% of 9M 2020 Net Income. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In March 2020, UTMD repurchased 80,000 of its shares in the open market at $80.32/ share. In September 2020, UTMD repurchased 7,000 of its shares in the open market at $78.67/ share. &nbsp;The total 87,000 shares repurchased in 9M 2020 were at an average price of $80.19/ share. &nbsp;In May 2019, UTMD repurchased 5,000 shares at $79.52/ share. No other shares were repurchased in 2019. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders, preferably shares from institutional investors who blindly follow proxy advisory firm bureaucratic recommendations which don&#8217;t care about performance or support management. UTMD&#8217;s closing share price at the end of 3Q 2020 was $79.87, down 26% from the $107.90 closing price at the end of 2019. &nbsp;The closing share price at the end of 3Q 2019 was $95.84. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At September 30, 2020 compared to the end of 2019, UTMD cash and investments increased $3.5 million to $46.3 million after using $3.1 million cash for dividends to stockholders and $7.0 million cash to repurchase 87,000 UTMD shares. At September 30, 2020, working capital was $53.6 million compared to $51.4 million at the end of 2019. &nbsp;Net Intangible Assets were 36.2% of total consolidated assets on September 30, 2020 compared to 40.2% on December 31, 2019. &nbsp;Even with much lower demand as a result of the COVID-19 pandemic, UTMD was able to reduce inventories $0.6 million at September 30, 2020 from December 31, 2019. &nbsp;Consolidated Accounts Receivable (net of allowances) declined $0.5 </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>8</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>million at September 30, 2020 compared to December 31, 2019. &nbsp;UTMD was able to maintain the aging of trade receivables at the end of 3Q 2020 at 36 days, the same as at the end of 2019, despite increased financial stress of hospitals and international distributors during the pandemic. </FONT></P>
<P style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Stockholders&#8217; Equity at September 30, 2020 declined only $2.7 million from the end of 2019 despite a $10.1 million reduction from $3.1 million in cash dividends and $7.0 million in stock repurchases.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Financial ratios as of September 30, 2020 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 15.8&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 3Q 2020 sales activity) = 36&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 3Q 2020 CGS and average inventories) = 2.5&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2020 YTD ROE (before dividends) = 10%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward-looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><I>www.utahmed.com</I></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>9</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Third Quarter (3 months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:225.9pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2020</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2019</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:225.9pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 10,479</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 12,494</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>(16.1%)</P>
</TD></TR>
<TR><TD valign=top style='width:225.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>6,497</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,379</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(12.0%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:225.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,588</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,371</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:76.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(17.9%)</P>
</TD></TR>
<TR><TD valign=top style='width:225.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,588</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,448</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(19.3%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:225.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income </P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>2,933</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,705</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:76.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(20.8%)</P>
</TD></TR>
<TR><TD valign=top style='width:225.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Diluted EPS </P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ .803</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ .991</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(19.0%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:225.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,654</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,737</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:76.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Three Quarters  (9 months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:225.9pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2020</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2019</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:225.9pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 30,168</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:58.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 35,073</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>(14.0%)</P>
</TD></TR>
<TR><TD valign=top style='width:225.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>18,283</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>21,652</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(15.6%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:225.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>9,428</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>12,954</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:76.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(27.2%)</P>
</TD></TR>
<TR><TD valign=top style='width:225.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>9,553</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>13,150</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(27.4%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:225.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income </P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,386</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>10,369</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:76.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(28.8%)</P>
</TD></TR>
<TR><TD valign=top style='width:225.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Diluted EPS</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 2.008</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 2.774</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(27.6%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:225.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,678</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,738</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:76.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse><TR style=height:21.6pt><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2020</FONT></P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2020</FONT></P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2019</FONT></P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2019</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>$46,294</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>$42,352</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>$42,787</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>$37,393</P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>4,277</P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>3,792</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>4,742</P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>5,067</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>6,304</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>6,580</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>6,913</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>6,711</P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>385</FONT></P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>393</FONT></P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>444</FONT></P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>342</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>57,260</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>53,117</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>54,886</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>49,513</P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>11,036</P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>10,812</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>10,728</P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>10,266</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>38,776</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>39,616</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>44,173</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>44,315</FONT></P>
</TD></TR>
<TR style=height:21.15pt><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>$107,072</P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>$103,545</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>$109,787</P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>$104,094</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>651</P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>560</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>1,098</P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>786</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>79</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>79</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>101</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:18pt'>85 </P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,897</FONT></P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,604</FONT></P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,249</FONT></P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,815</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,627</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,243</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,448</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,686</P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>2,132</P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>2,135</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>2,239</P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>2,170</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>346</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>356</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>376</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>385</P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>1,9 95</P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>1,995</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>2,110</P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>2,443</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Deferred Income Taxes</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>557</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>528</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>521</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>426</P>
</TD></TR>
<TR><TD valign=top style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>98,415</FONT></P>
</TD><TD valign=top style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>95,288</FONT></P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>101,093</FONT></P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>94,986</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:203.85pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:68.8pt><P align=right style='font:10pt Times New Roman;margin:0'>$107,072</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:72.95pt><P align=right style='font:10pt Times New Roman;margin:0'>$103,545</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.9pt><P align=right style='font:10pt Times New Roman;margin:0'>$109,787</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:70.85pt><P align=right style='font:10pt Times New Roman;margin:0'>$104,094</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'>10</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utahmedcom-20201027_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK611ND10HVJLCM79P]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://UTMD/20201027"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utahmedcom-20201027.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utahmedcom-20201027_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK611ND10HVJLCM79P]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://UTMD/20201027"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utahmedcom-20201027_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK611ND10HVJLCM79P]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://UTMD/20201027"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utahmedcom-20201027.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utahmedcom-20201027.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK611ND10HVJLCM79P]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2020-01-31' xmlns:fil='http://UTMD/20201027' xmlns:dei='http://xbrl.sec.gov/dei/2020-01-31' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://UTMD/20201027' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utahmedcom-20201027_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utahmedcom-20201027_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utahmedcom-20201027_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/numeric'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/non-numeric'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://fasb.org/us-gaap/2020-01-31' schemaLocation='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd' />
	<import namespace='http://xbrl.sec.gov/dei/2020-01-31' schemaLocation='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd' />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>utahmedcom-20201027_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utahmedcom-20201027.xsd" xlink:type="simple"/>
    <context id="D201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D201027" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D201027" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D201027">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D201027">2020-10-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D201027">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D201027">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D201027">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D201027">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D201027">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D201027">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D201027">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D201027">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D201027">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D201027">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D201027">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D201027">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D201027">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D201027">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D201027">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140559854528072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Oct. 27,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ\I=,!"47&ZO]'V7B(. I'LD(-D%))Y[VY&GO*:6#GI:;8AVK4'-%?Q0?33
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M4$L! A0#%     @ *8);4:YQQ>CN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ *8);49E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  I@EM1_O+&L\L#  !+#@  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ *8);48.II0/4 0  ,@8
M  T              ( !#@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  I
M@EM1EXJ[',     3 @  "P              @ $-#@  7W)E;',O+G)E;'-0
M2P$"% ,4    "  I@EM1'#AEZC\!   \ @  #P              @ 'V#@
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ *8);420>FZ*M    ^ $  !H
M             ( !8A   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ *8);4660>9(9 0  SP,  !,              ( !1Q$  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  D1(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utahmedcom-20201027.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="utahmedcom-20201027.htm">utahmedcom-20201027.htm</File>
    <File>utahmedcom-20201027.xsd</File>
    <File>utahmedcom-20201027_def.xml</File>
    <File>utahmedcom-20201027_lab.xml</File>
    <File>utahmedcom-20201027_pre.xml</File>
    <File>utmd_ex99.1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utahmedcom-20201027.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "utahmedcom-20201027_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "utahmedcom-20201027.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utahmedcom-20201027_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utahmedcom-20201027_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "utahmedcom-20201027.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 34,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fil",
   "nsuri": "http://UTMD/20201027",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utahmedcom-20201027.htm",
      "contextRef": "D201027",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "role": "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utahmedcom-20201027.htm",
      "contextRef": "D201027",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Fiscal Year End"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Period End date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "SEC Form"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Registrant CIK"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Number of common stock shares outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Current with reporting"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Tax Identification Number (TIN)"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Trading Exchange"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://UTMD/20201027/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r5": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001445866-20-001623-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001445866-20-001623-xbrl.zip
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MA'N18N>K!M>P-0E2)<CZ 5:I['FCPH[$,Q3)R0J(LO0:#X9_\3<8B3E,'[7
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MJ?U(V*9$[7*R@VW! S2GZ>[_!E!+ P04    "  I@EM1!2>PXA@"   7!P
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M4=@KXT>/BGHUG2+ACOC!KQCS$1W(]HK>CT:(*GA2.,2$+YO:8\(;H<.R$TI
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MPRJ0",<E;1Y=GTN%Z%]DMG7RM8KKE(0UFT *G)6ZYKKL"(P Z*7FBF,N6P'
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M#U4.Z@X</F^&_YGM7BH$E#<;.!#V!6YN<MN6%)$]@DTX>@!+E\^L$Y*AA1O
M/9?BBAGEG7*[<\$B0&V$VQ:]KEEO&N*,G.#<GKW_Y5*T*+AWC%(^BYPW\I=W
M;V^_P/\OV",_R,9@V?$W^ %<[QIJCQ_!6Q6F+])R^!]4@:@6@8%LT W_FQ.E
MU[<7RZCO&ZN\![L>A_;;RZ)77Y/>GU*"3T6CO-LN]EIL=:]#,FH.:8"=R$%Q
M?\3!C<GZM#BFUR#)?RH1Y]$]'O_"O_WY_/SR\L.'_&B%?)_F>ZP:\)9CS-N_
M7%5UP"CPYG0B_WSYZ;ATC3A5RP>2Y<05HVARV?[*M)YJOJIDK4.DN:-;JO:J
M?*H;HKE]G= 9JMV-Q[26R.]CI8206*J>&UN5J"\3;?A^BU%M.1 Z9MB)[-??
M7+:COEGIT=3!$DY["4/HZZK5ZA#VH ^8J?;7'F-. :P8Y2'I!T,O:+TFC("]
M:HJKT/'P++E25:R]2QV0W.G]@B)_^4/J#9>*V>Z'M ?5H@VWL)]>K*KI%O:,
M%V>$?/WX8Q@@FK94B[R$(0QT=?BC&R!&3^W]^ ;(L& ,OW@#Y$-(438_I/T!
MFF.9V+W$(8$F:<27\9(TBZ:KQG^>_:$7#,T79W^D5[8_@AE2SV$M/5GBM+#A
M%<.+'7W/X.?TML=]Z'<S'<VHSQ O5(/5G!E=+V>9'1I8F2'S&/ M1WPS'\5!
M;'L*NW!#9QSC3?BE/V%?(R=\L[,M>P=W/#TX<+T<>CM&0_<[*V2K38M'V[/'
M90=#ZA>,N$WLF=T:+(T&4YUY'OL<8USAYZ\WK'-#(8R@$*[\6 3N>: F,&)P
M-,<8H@V\ RTJ\W630.JWS*2I9&[FY?DA)D'. =ZM-SH'[>NN'4Z2T:MQ$WFH
M=]P[G!^M> 7XXIU3%$'S^?(3(_7Y(SERZEG'?V5=8/UEQX:Z,4,O=R8LBC]:
M?H#Z$=U@=1T00WY_M<U$_6></,7>VRT_F3?H=FOZO/G?0>A-GC E1H8/-^9J
MV47@(,SOX=+7T<V=7-&U>6CL+STTOHA#8J\TON<UA?9CFOV7O%A#0P\.GV&1
M02];?J.!/+(N_G<%F<NSWS5.3-KQS+YW3D:A8W\[L>^@L3>V]V0_1Z=%@HA%
M[/$WS)+S)R>D9M_\V>KB?V7[0R0Q8R=YKN^<) .21#201M/H\3;-R<%D/G?B
M8A;0A'N\"ME^F$)-H9 *$X%./-_DJ^]BVM='U[^'-Q0F+B$Q$"J]-> )58^!
MBR .T-)=$,+4^&R<Y)2I[$/^LV?,N:),%=;Y\,]C%MJQPU-?7'\,I,&HX1.>
M-3H/9T$$WV(WE,QKCS'9Y^2)YA^3TAZ=$!8[XNFCXB_9)*8KXDCLV<QSQY0T
M<U>D!4[[E,W!DT%E;F$VC79ISHS(E1').4VES#2=,=/OJU;-A)D\$:MR1 ;;
MY(C43YY@B"%1(X6E;?(TJ][MP5#=<<Y*W3&<DWS6O +9:89*_6R4VDRB=LTV
M^00H7)=/4C9IE<(J+B@SMY>>;8M::"/[^J=W/[^_KG^N;D8%:*INF7OLW# V
M]RBTH%W^RDPP"C<G<=>Z V9P8&V^?%MK!NQ_@Q5L3.[1-Y7+"%LBPHV*[.77
M+\N&W:R4:,OGN.'.NL/5G;4L@L.E(MBVR&GZ&C/4H(AI^OK+WXQ(]=84J9WN
MBF=?+_:U,775@=;;7^?]X># =\7>0>^*,(.##6:P,9$%]D&\O+WMBAUFK!'O
ML(MM\?QLJ<PV+*.FUF9GA[4M=D!-5_F,][(OPA3UEIXDFA<R4V]Q7^PP;;E_
MN!U0JP27#%UVCX%GQZZ'P(S!G;A*^O#/C.<1PW^X-_3IP4&('Y\6',%=T,6'
M'D*8AFDDX<!XF) [G=GC6/@"3^+@1&#^H!>5<'T6,2Q'#H>N*\(F9L#.))P/
M.C+AL06/)=')7;1B#)(0H%0Z+9_LB!$$6K;A+&*:P&:<V5&LLDL.@B7AAQ"&
M2S;-H>L>[ FA&'&_+6&!Y>'9X(.  JE2QZ_";/;@V+ .SXE?=>*,T7\NB<!Y
M#>[N(B?FV)0(N78/7R#8DW3)$O01P8L^V-Y=#C)MT;.<19^4?1*8G.N/0T0T
M(X#"HZ')T97XJG" PR?'_N9P=+.LQY=:T:P,A!ZR0 C3)D! W;L[)R2\3>AS
M@142+H/F" DYH1#I,/J9-9-=+ R*,R81G&<-"F25?(NCU%'TBM]DI@+=VA3#
M6_),@8H<=XI)2-WB\'MFJI>Y_U-427A"Q\AJ3L5 U3-4Y 0.EX"3!2_.G#&*
MDO>L[L"WOG5C/'CP#H0O" 74F0W\,,9AE*@%COZ71>T$OO3F$WBZ"7C0)G".
M3[0A-J4=<Y#B*U3_/B&L(51L)A92,(<$&<-Q)K"&N'N"8O7FXWB.2H0 /$G[
M)'=/B*T(BE ^K#8'DMK@+.AB%C3!_T]<"&&4J-,S*(YY%*$/KA<]N*!'/7?&
M;IZCV)FRCOR0P^T>2S5N<P@WCO@Y_GWN<H*EGCL/ H0FO)D#;0A7>>6/6>?\
MYNJ8$48108'F6TX7"9LA=L7-*OC&'.),]L$9A7.\#M04KMJ:F_J-=VL:_BP,
M[MR8\4\7]%;9=5R97MKT)J[^K9O$@[<,%1HN\(]*EO0*(#NCK_;K MG%SO?X
MQ/412_;-(-MQ,VIN@^97 LBI*P'SFR!),LN689MK]E8S?NF_YEX>6?W&F=7-
MO<)IS!^6M&;C/58/W103S<> \K;SV=XD6JR1V1X48Y/W,]N@U^1LZ]W#G&W8
MUS><;3'9IJIM=>K<8"X/E7/7F\MZ0>-;[#:ENN_G,("3Y37?KC_1$ZQS3Q_R
M/3QZS<V;X[H9=>WN&'V]RCV[1GSR 6AC&H2)B75LXU'L7\OQI>@NBSQ=RBPM
M* ].HD;A_6L&'3<M<Y_A&&!3-9$K'B4GY2Y(OEA;]O9BG2W-5SU0V3(JHQH.
MTV#@1&NJL8KHED4'I,!:1W3:V;Y^=>*B$(FC)P4+L]C^[KR0'4Q'A-G-E?^!
MB)ENY37KB]S!=+-^0G[+8@CSW%\4PTTN9EIPK<K28VG9@X7P\#'\<A^$KKP.
ML4?!HU-T(\7!O4->6BK6D"F1D#BP*;#<$W<]6)"KLC!%QOTN&UHG.OSPPL+W
MD;E?,_8T>R,@M/6-7/F-06L.-L%MW9H,+VE,6]1M>+DYG3NI['#P2[VCV@^[
M4D4UDC+7S5(^A 3-@Z)U5;+F81&[(B]S_13LO>9@UMKN=R5<6>]@;<W?DAAU
M\^?1 Z(- 52Z&^0XMX;RN3YQ>Q"+'8"K[$I,B@Z]EZ$H984D]I*4NVDN+2UR
M6,1J@RV(;5_D*)#K0'>B2SO$2,*(O7<P,$T>(V_M[X>I7A/A,FJ4B6E=F/H;
ME1IJ27BLI2C4!R LO9>R/Z5>\I>A.$]>!IE8Y^KE[)QZ=?+$06Y&PP*YA[@9
M76,\)Y::/DP=6BU'>Y>; SX760=]+H)]I^Q<U')*SI6_ZD(GXN7*%3;CY>=#
MYP[O8_G-"D^RBY\"!DIG/O4CF47"RV'_WSR*Q0T05?'.UND.[DI#B1?ZEUDZ
M=%54=9LC,R0^H4DY<6+;]9B;%"N?,+Q)"CEM2>%YM8A0U18TEOX2H;&VX+%<
M:%HF@EPD'DUX4A2E(O#UQ303F94T"UUHR>7I3-GL(/[8U/W.8:8D_V1#WL1]
M(^O\?/WI6,E_-7$Y9XR2Y"U*SPJ>D+E%3I8,7Y\XT<R-':)NY,2XW# &:#1)
M'=-ZK\2[@GJ>)R6)PDR'<.1,!$&V!\.A01=3SN[<[_#4.'1CRBR8VOP9F,\Y
M)K3P5D&<P@?'GJAPAN+=4ZC^R/%<Y]$1*2](:Y:B!*W+C0.4YF\^5JIW\<(6
MKUVG-HP7VGT6\T/BBWYX5M*6!U]X$7.^HQ1BFM4DFQ@V W%VINZ8Q/J!5BV;
M\#:VHP=<1B=\=-*L/- G(FB*DEI\QYG DL"X031(#3RYGL?3W>8QYM:! -M<
M.P3S<(P#A-XB&Z;N#A,N[N8P60YT-K-'F&2(64^DC: C'&N,XXT>H!5*(BQ<
M4*N-I/YL+# +<66)I*1).SEFAK&, E"/90IUE.&1A,_\P#^AA7 Q/@&FC-8;
MI\6_=_%78#PX:W2NKLZ.F0V]QNZ_:6UHT?W(29.DH.\TW$U\&Y$P::9JODI%
M-2/YV0MZ#6WOQ:<T2Z%A:'V,ILED41;>';S*2*K<!FY1RR,)D[E#3!/XWK/<
ML[*<3-L'--HA:20QG<E4'UM(HQC3,1L!Y]E>Q%OY^?UUDH^9SS?$;V$(2#SM
MA.Z4A/8.5@+6UY=B<GYSQ6!Z\[,KM[,VU7-B!(^X1R:VO[/.Y?O;XS*V2Y=:
M;M0@BS"W62Z#^>"9J9C/BL+MX@[I1+@,E%-*G#>R/<0N3-? <[\YC#3S1,X#
ML(!,&98P@OEW*<,2# Q8&1W8Y &V.5C;O/:53)$),4L&%GFX,0+]Z0AAY,6M
MAG8EU+J81QD_XZ9#']O?26Q$C&<RD"R'YKF2,Q]J(9CC$-@!UP1:DL5L)<]\
M_4C9O?CK/9@%,;XB:*9N@$:5?> ;B<(63S&P?M<WQV4;K(]IO7P22@8Y<GP'
M]0E*([4#EA)H5U#BZ3JURILYI97+#A<L '0Z3A&4,@\OR=\1VUB]*W3'GX@[
M=)P2QQX_"-N10GO)!.761TI:#7Q+,HE1S_+-RW/3K4I0BPF9T/&-,P-C> 2K
MFVCWBF_WD6MGX$'++"3;613PA\%.HA%A@N)M$/]B&>2!::BF61)7JJ]-_VI8
MA:H^EMON2_J8NI.)Y^3Z&.I)'QN>'86-GQQ":[$O< 8SN@KC64K5$3 EE ],
M=7@0E"^'8UR^KON@?!4^XTIQ$(NQ+#BUBG7KC&H+W,8FNE\M1\LH:%RN$$JR
M')!E#6H:EQ7$EBS'8*K''/R=NI#Y!6(68"3K<G+3K%,#OK =3MTQ9VJ#I9RY
M8T[L6N5 5<L7MR'.&Y0#9!Z*#MT"Y>\'U*$(/-@_&!V*.'KED%Y[T:$8RGA
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MBJYU*X'UX=6ATC6KHE=Y(MHD3U61$WFXZ71$5E\:M#KL(HZM? DL* &)/,F
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M!24-CY 6SVCI=K%]/B2\@(9.$%67>.(FS]1&Q*UB)G=N)^(VU9OZS)!-U=5
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M(4RWP63QN"L 3VM/P=1)ZJVZ",XY<G'N)B 27C CSDO6APL.7R,\B(S"P)[
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M"P#GAZ,UZL"4M4!.#9RR=I089D =J!++Y'<<J(Z@1*$#I8T2E Y5?^E==7A
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M=&%H;65D8V]M+3(P,C Q,#(W+GAS9%!+ 0(4 Q0    ( "F"6U$%)[#B& (
M !<'   ;              "  :<1  !U=&%H;65D8V]M+3(P,C Q,#(W7V1E
M9BYX;6Q02P$"% ,4    "  I@EM1[(.?XR,(  "63P  &P
M@ 'X$P  =71A:&UE9&-O;2TR,#(P,3 R-U]L86(N>&UL4$L! A0#%     @
M*8);4?\2&8RL!0   C4  !L              ( !5!P  '5T86AM961C;VTM
M,C R,#$P,C=?<')E+GAM;%!+ 0(4 Q0    ( "F"6U&)G$+!\SP  (?B 0 /
M              "  3DB  !U=&UD7V5X.3DN,2YH=&U02P4&      8 !@"B
) 0  65\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
